Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 1-week, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Outpatients With Depression Who Completed 8 Weeks of Treatment With Saredutant 100 mg Once Daily

NCT00429260 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00429260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00429260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 1-week, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Outpatients With Depression Who Completed 8 Weeks of Treatment With Saredutant 100 mg Once Daily
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2007
Completion date
June 30, 2007
Enrollment
125 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder